Theriva™ Biologics Reports Second Quarter 2023 Operational Highlights and Financial Results
ET -
- ET -
ROCKVILLE, Md., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today reported financial results for the second quarter ended June 30, 2023, and provided a corporate update. - These results build on the impressive safety, biochemical and mechanistic data presented last year, demonstrating that VCN-01 improved tumor immunogenicity in previously immunotherapy refractory patients.
- Second Quarter Ended June 30, 2023 Financial Results
General and administrative expenses increased to $2.7 million for the three months ended June 30, 2023, from $1.5 million for the three months ended June 30, 2022. - ET to discuss its financial results for the quarter ended June 30, 2023 and provide a corporate update.